Compare Ginkgo Bioworks Holdings Inc (DNA) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs ING Groep NV — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while ING Groep NV trades at $32.76 (market cap $93.58B). The key difference: ING Groep NV is far larger — about 158.5× Ginkgo Bioworks Holdings Inc's market cap, and ING Groep NV pays a 3.86% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ING | |
|---|---|---|
Market Cap | $590.53M | $93.58B |
Sector | Health | Financials |
52-Week High | $16.14 | $32.96 |
52-Week Low | $5.48 | $22.45 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
ING trades at $32.30, down 0.28% on the day, with strong analyst support (62.5% buy ratings) and bullish technical signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.63 exceeding the $0.60 forecast. Revenue growth remains steady at $22.9B for 2025, while net income margin stands at 27.84%. Recent corporate developments include a new global subscription banking model and management board appointments.
The outlook remains positive given ING's earnings momentum, attractive valuation (P/E 12.95), and strategic initiatives. Key risks include negative operating cash flow trends and exposure to European banking sector volatility. With intrinsic value estimates around $34 from DCF analyses, the stock offers potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
